Finding the Optimal Partner to Pair with Bispecific Antibody Therapy for Multiple Myeloma

Abstract

BCMA/CD3ε-targeted bispecific antibody (BsAb) therapy represents a promising T cell–redirecting immunotherapy to treat relapsed and refractory multiple myeloma. However, rational combination strategies will most likely be key to achieve a long-lasting immune response. In this issue, Meermeier and colleagues investigate BsAb therapy in a syngeneic multiple myeloma model and elucidate that partnering with cyclophosphamide is associated with tempered activation, mitigated exhaustion of T cells, and is superior to pomalidomide or bortezomib in enhancing durable anti–multiple myeloma efficacy.